ReviewVisceral medicine2021
Surgical Therapy for Perihilar Cholangiocarcinoma: State of the Art.
Review in Visceral medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Article
- Current issues in clinical staging of perihilar cholangiocarcinoma-a European snapshot survey.Updates in surgery · 2026Article
- Standardized reporting of extrahepatic cholangiocarcinoma.Abdominal radiology (New York) · 2026Review
- Intraoperative indeterminate frozen-section margin leading to an unintended R1 resection in perihilar cholangiocarcinoma: a case report and decision-making framework.Frontiers in surgery · 2026Article
- Prognostic implications of morphological subtypes in a surgical cohort of perihilar cholangiocarcinoma: the overriding impact of nodal status.International journal of clinical oncology · 2025Article
- Western and Eastern experience in treating perihilar cholangiocarcinoma: retrospective bi-centre study.BJS open · 2025Article
- Preoperative Imaging Assessment and Staging of Perihilar Cholangiocarcinoma: Tips and Pitfalls.Journal of the Korean Society of Radiology · 2025Review
- Parenchyma-Preserving Hepatectomy in Perihilar Cholangiocarcinoma: A Chance for Critical Patients?Visceral medicine · 2024Article
- Systematic Review of Preoperative Prognostic Biomarkers in Perihilar Cholangiocarcinoma.Cancers · 2024Review
- Gallbladder cancer mimicking perihilar cholangiocarcinoma-considerable rate of postoperative reclassification with implications for prognosis.World journal of surgical oncology · 2023Article
- Review
- Confounding by Indication Is a Major Issue in the Available Evidence on Role of Portal Vein Resection in Patients Undergoing Curative Surgery for Klatskin Tumour.Visceral medicine · 2022Article
- A novel nomogram for adult primary perihilar cholangiocarcinoma and considerations concerning lymph node dissection.Frontiers in surgery · 2022Article
- Klatskin Tumors: Challenging as Ever.Visceral medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSurgical therapy still offers the only chance of long-term survival for patients with perihilar cholangiocarcinoma (pCCA). The aim of this narrative review is to summarize the current standards and challenges in the surgical treatment of pCCA. SUMMARY: After imaging and defining resectability, the first step towards optimal surgical treatment is optimizing biliary drainage and preventing cholangitis, followed by securing adequate future liver remnant volume and/or function. The main goal of resection for pCCA is achieving radical resection and ultimately long-term survival. In order to achieve radical resection, several points will be addressed (e.g., vascular resection and reconstruction, intraoperative frozen sections, right versus left hemihepatectomy, and the usefulness of preoperative [chemo]therapy). KEY MESSAGES: In order to optimize long-term outcomes for patients with pCCA, collaboration between leading centers should be increased. In addition, this collaboration is necessary to design large prospective randomized controlled trials, as the incidence of pCCA is low and the number of resectable patients is even lower. Currently, most results are based on small retrospective cohort studies resulting in low evidence. In order to properly investigate how to improve long-term survival, we need to set up trials to confirm the results of small series suggesting the positive effect of preoperative chemotherapy and extended lymph node resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.